CR20210202A - Compuestos, composiciones y métodos para modular la actividad cdk9 - Google Patents

Compuestos, composiciones y métodos para modular la actividad cdk9

Info

Publication number
CR20210202A
CR20210202A CR20210202A CR20210202A CR20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A
Authority
CR
Costa Rica
Prior art keywords
modulating
compositions
compounds
methods
cdk9 activity
Prior art date
Application number
CR20210202A
Other languages
English (en)
Inventor
Joseph VACCA
David Freeman
Andrew Tasker
Peter Mikochik
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of CR20210202A publication Critical patent/CR20210202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de CDK9 que son derivados de pirazol[1,5-α]pirimidina y sales de los mismos, correspondientes a la fórmula (I): (I).
CR20210202A 2018-10-30 2019-10-29 Compuestos, composiciones y métodos para modular la actividad cdk9 CR20210202A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
CR20210202A true CR20210202A (es) 2022-02-08

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210202A CR20210202A (es) 2018-10-30 2019-10-29 Compuestos, composiciones y métodos para modular la actividad cdk9

Country Status (21)

Country Link
US (3) US11155560B2 (es)
EP (1) EP3873911A4 (es)
JP (1) JP7385658B2 (es)
KR (2) KR20210068597A (es)
CN (1) CN112996790B (es)
AU (1) AU2019370200B2 (es)
BR (1) BR112021008176A2 (es)
CA (1) CA3118472A1 (es)
CO (1) CO2021005502A2 (es)
CR (1) CR20210202A (es)
DO (1) DOP2021000066A (es)
IL (1) IL282254B2 (es)
MA (1) MA54092A (es)
MD (1) MD20210033A2 (es)
MX (1) MX2021004769A (es)
MY (1) MY210039A (es)
PE (1) PE20212196A1 (es)
PH (1) PH12021550857A1 (es)
SG (1) SG11202104229WA (es)
WO (1) WO2020092314A1 (es)
ZA (1) ZA202102609B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282254B2 (en) * 2018-10-30 2025-08-01 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
EP4240422A4 (en) * 2020-11-05 2025-05-07 Kronos Bio, Inc. Compounds and methods for modulating CDK9 activity
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
JP2024543136A (ja) * 2021-11-24 2024-11-19 クロノス バイオ インコーポレイテッド （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態
CN119630666A (zh) * 2022-07-22 2025-03-14 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
EP0714898B1 (en) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
ATE365740T1 (de) 2002-05-10 2007-07-15 Smithkline Beecham Corp Substituierte pyrazolopyrimidine
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
KR20050033659A (ko) * 2002-09-04 2005-04-12 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로[1,5-ａ]피리미딘 화합물
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP1537116B1 (en) * 2002-09-04 2010-06-02 Schering Corporation Pyrazolopyrimidines suitable for the treatment of cancer diseases
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
EP1697369A1 (en) 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
KR20070051325A (ko) 2004-08-13 2007-05-17 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
EP1836205B1 (en) 2004-12-21 2009-06-10 Schering Corporation PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
CN101316847A (zh) 2005-10-06 2008-12-03 先灵公司 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
KR20090019796A (ko) 2006-05-22 2009-02-25 쉐링 코포레이션 ＣＤＫ 억제제로서의 피라졸로[1,5-ａ]피리미딘
CA2688616A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
EP2173346A2 (en) 2007-06-27 2010-04-14 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
CN102143746A (zh) * 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
WO2010074284A1 (ja) 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
EP2509602B9 (en) 2009-12-04 2017-11-01 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
KR101478889B1 (ko) 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
WO2011108689A1 (ja) 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
CN102985426B (zh) 2010-07-13 2015-10-07 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2621926B1 (en) 2010-09-30 2017-08-30 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2802588B1 (en) 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted pyrazolopyrimidines as akt kinase inhibitors
GEP201706687B (en) 2012-02-17 2017-06-26 Millennium Pharmaceuticals Inc (A Delaware Corporation) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
WO2015154022A1 (en) 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6789962B2 (ja) 2015-03-09 2020-11-25 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3286192A1 (en) 2015-04-20 2018-02-28 AbbVie Deutschland GmbH & Co KG Substituted pyrazolopyrimidines and method of use
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6864674B2 (ja) 2015-10-01 2021-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビアリールキナーゼ阻害剤
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HK1259453A1 (zh) 2015-11-19 2019-11-29 缆图药品公司 可用於治疗与ntrk相关的病症的化合物和组合物
US11112410B2 (en) 2016-04-13 2021-09-07 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
IL282254B2 (en) * 2018-10-30 2025-08-01 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity

Also Published As

Publication number Publication date
WO2020092314A1 (en) 2020-05-07
IL282254B1 (en) 2025-04-01
EP3873911A4 (en) 2022-06-22
SG11202104229WA (en) 2021-05-28
MA54092A (fr) 2021-09-08
US20200131189A1 (en) 2020-04-30
CO2021005502A2 (es) 2021-09-20
US20220002305A1 (en) 2022-01-06
MX2021004769A (es) 2021-08-24
US11845754B2 (en) 2023-12-19
MD20210033A2 (ro) 2021-10-31
AU2019370200B2 (en) 2024-12-19
JP7385658B2 (ja) 2023-11-22
KR20210068597A (ko) 2021-06-09
IL282254B2 (en) 2025-08-01
MY210039A (en) 2025-08-22
JP2022505268A (ja) 2022-01-14
DOP2021000066A (es) 2021-10-31
CA3118472A1 (en) 2020-05-07
CN112996790B (zh) 2023-11-03
EP3873911A1 (en) 2021-09-08
AU2019370200A1 (en) 2021-06-10
CN112996790A (zh) 2021-06-18
PH12021550857A1 (en) 2021-12-06
US11155560B2 (en) 2021-10-26
IL282254A (en) 2021-05-31
PE20212196A1 (es) 2021-11-16
BR112021008176A2 (pt) 2021-08-03
US20240132506A1 (en) 2024-04-25
ZA202102609B (en) 2023-02-22
KR20250174699A (ko) 2025-12-12

Similar Documents

Publication Publication Date Title
CR20210202A (es) Compuestos, composiciones y métodos para modular la actividad cdk9
CO2020007244A2 (es) Inhibidores de kras g12c
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
MX2023001876A (es) Derivados de rapamicina.
UY38070A (es) Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
MX2018005268A (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
UY31998A (es) Nuevos derivados de imidazo[1,2-a]pirimidina, y sus nuevos usos como inhibidores de met
CO2022001860A2 (es) Derivados quinolina como inhibidores de proteína quinasa
MX391647B (es) Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
MX377489B (es) Compuesto de pirazolo[1,5-a]pirimidina.
ECSP20026023A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
UY28903A1 (es) Nuevos derivados de piridazinona
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
DOP2021000063A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen